항생제는 현대 의학의 기본 요소이며 전염병의 부담을 줄이고 사망률을 줄이거나 심지어 억제하는 기록을 가지고 있습니다. 원인 병원체를 식별할 필요 없이 감염을 신속하게 치료할 수 있는 능력은 감염의 유병률을 억제하는 결과를 가져왔고 수술, 장기 이식, 화학 요법, 신생아 및 소아 치료 형태의 현대 의학에 여러 가지 기회를 열었습니다. 그러나 이러한 모든 이점은 언급된 이점과 더 많은 이점을 잠식하고 있으며, 이로 인해 WHO는 항생제 이후 시대의 가능성과 관련 항생제 내성 부담에 대해 경고하게 되었습니다. 항생제 내성이 지속됨에 따라 2050년까지 항생제 내성 감염으로 인해 연간 사망자가 1,000만 명이 넘고 세계 경제에 대한 비용 부담이 최대 100조 달러에 이를 것으로 예상됩니다.
항생제 내성 관리 및 억제는 다면적인 임상, 규제 및 경제적 접근 방식입니다. 이러한 단계는 규제 프레임워크 개선, 파이프라인 펌핑, 새로운 협폭 항생제 및 대체 치료법 개발, 치료 목표 변경, 표적 항생제 개발 장려에 이르기까지 다양합니다. 항균 전략의 주요 측면은 표적 항생제, 즉 특정 종이나 속의 특정 항균 약물을 개발하고 상업화하는 것입니다. 이 연구에서는 이 접근법의 과제와 장점을 논의하고 좁은 스펙트럼과 표적 항생제를 식별하는 데 도움이 되는 몇 가지 권장 사항을 강조합니다. 이 리뷰는 리뷰와 시장 동향을 포괄적으로 편집한 것은 아니지만 표적 항생제 분야의 최근 발전과 널리 퍼진 역학을 강조하는 데 사용됩니다.
저항성 박테리아 감염을 퇴치하기 위한 유망한 전략은 감염 및 그에 따른 저항성 위험을 예방하고 항생제 파이프라인을 재정비하는 것입니다. 경제적 조치와 규제 조치의 혼합, 이용 가능한 항생제 사용을 보존하여 저항성 위험을 늦추기, 저항성 감염 가능성을 줄이기 위한 미생물 공격 치료법의 새로운 접근 방식 개발, 종 특이적이고 좁은 범위의 항생제 개발, 다음과 같은 치료법 개발 등이 있습니다. 미생물 제제보다 숙주 표적이 더 중요합니다.
현재 사용 가능한 항생제의 유용성을 높이기 위한 개선된 사용법은 실제로 저항의 위험을 억제하는 최선의 전략이지만 잘 정의된 추적 메커니즘이 부족하고 균일한 자원의 가용성이 이 접근 방식의 잠재력을 방해합니다. 대안적인 접근 방식은 표적 접근 방식으로 새로운 항생제를 개발하여 원인이 되는 병원체를 공격함으로써 미생물군에 미치는 영향을 줄이거나 최소화하는 것입니다. 스펙트럼 항생제는 흔히 일반화되고 거친 접근 방식으로 간주됩니다. 이러한 약물은 원인이 되는 병원체를 처리할 뿐만 아니라 다른 미생물군집에 눈에 띄는 손상을 유발합니다. 따라서 이러한 비표적 치료법은 궁극적으로 질병 발생 측면에서 중요한 결과를 초래할 수 있으므로 새로운 항생제 세대의 필요성과 궁극적으로 이러한 문제를 해결하기 위한 변화의 필요성을 촉구합니다. 최근 후기 단계 임상 개발(표적 병원체 특정 항생제)에 도달한 일부 잠재적 후보로는 Ridinilazole, Afabicin 및 AR-101이 있습니다. 내성 박테리아에 대한 잠재적인 치료법이 될 수 있는 일부 전임상 후보가 있습니다.
항생제 R&D 파이프라인의 눈에 띄는 붕괴는 다음과 같습니다. 이 보고서에서 더 자세히 논의되는 경제적 문제와 규제 문제의 결과입니다. 이러한 과제를 극복하기 위한 솔루션은 항생제 개발에 대한 규제 및 경제적 접근 방식을 더 잘 조정하고 조정하는 것이 좋습니다. PPP(공공 민간 파트너십)는 R&D 초점을 충족되지 않은 요구 사항에 맞추는 잠재적인 단계가 될 수 있습니다.
제한된 인구 항생제 약물과 같은 새로운 규제 전망 및 각각의 접근 방식 미국 전염병 협회(Infectious Disease Society of America)의 이니셔티브를 통해 내성이 강한 약제로 인한 특정 감염에 초점을 맞춘 소규모의 저렴한 임상 시험에 해당하는 약물 승인도 가능해졌습니다. 따라서 이러한 계획은 임상의의 항생제 소유권을 강화하고 임상 시험 비용을 절감하여 금전적 인센티브를 제공하는 데 권장됩니다. 이 보고서는 전반적인 광역 및 협역 항생제 시장의 현재와 미래 상태를 포괄적으로 논의합니다. 이 연구는 또한 표적 항생제 개발에 있어 정부, 임상의 및 제약 제조업체가 개발하고 배치한 주요 전략을 간략하게 보여줍니다. 이 연구는 추가적인 항생제 내성 위험을 줄이기 위해 취한 조치와 이 분야에서 취할 수 있는 경제적, 규제적, 임상적 접근 방식의 분석 권장사항으로 마무리됩니다.
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
- Way Ahead for Targeted Antibiotics: Current Status of Antibiotic Therapy and Future Roadmap, and Geography (North America, Europe, Asia Pacific, and South and Central America) Market Scope and Analysis
- Way Ahead for Targeted Antibiotics: Current Status of Antibiotic Therapy and Future Roadmap, and Geography (North America, Europe, Asia Pacific, and South and Central America) Market Size and Share
- Cut Flowers Market
- Health Economics and Outcome Research (HEOR) Services Market
- Grant Management Software Market
- Trade Promotion Management Software Market
- Europe Surety Market
- Enteral Nutrition Market
- Single-Use Negative Pressure Wound Therapy Devices Market
- Automotive Fabric Market
- Medical Collagen Market
- Railway Braking System Market
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
- GlaxoSmithKline PLC
- Pfizer Inc.
- Johnson & Johnson Inc.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi SA
- F. Hoffmann La Roche AG
- Eli Lilly & Company
- Otsuka Pharmaceutical Co. Ltd.
- AbbVie
- STADA Arzneimittel
- Cubist Pharmaceuticals
- Abbott Laboratories
- Shionogi & Co., Ltd.
- Daiichi Sankyo
- Astellas Pharma
- Sun Pharmaceutical Industries
- Lupin
- Cipla
- Top Antibiotic Startups
- Arixia Pharmaceuticals
- Acurx Pharmaceuticals
- Clemedi
- Locus Biosciences
- Bioversys
- Paratek Pharma
- Destiny Pharma
- Vedanta Biosciences
- Spero Therapeutics
- Oxford Drug Designs
- Entasis Therapeutics
- Nabriva
- Melinta Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.